Sana Biotechnology (SANA) shares more than doubled in recent Wednesday trading, a day after the company reported positive initial results from a study involving its hypoimmune technology in type 1 diabetes treatment.
On Wednesday, TD Cowen upgraded its rating on the stock to buy from hold.
Intraday volume in Sana topped 88.3 million shares Wednesday versus the daily average of 2.01 million shares.
Sana said late Tuesday the study showed that its hypoimmune technology enabled the transplanted islet cells to avoid rejection and produce insulin without immunosuppression.
Price: 4.21, Change: +2.56, Percent Change: +155.15
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.